Sugi Predict

Sugi Predict / Compounds / SCHEMBL29412263

SCHEMBL29412263

SCHEMBL29412263

CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 8/20 0.61
▸ NTSR2 O95665 1/20 0.59
▸ NTSR1 P30989 1/20 0.59
▸ SORT1 Q99523 1/20 0.59
▸ NPY1R P25929 1/20 0.55
▸ NPY2R P49146 1/20 0.55
▸ NPY4R P50391 1/20 0.55
▸ NPY5R Q15761 1/20 0.55
▸ F13A1 P00488 2/20 0.54
▸ TGM2 P21980 2/20 0.54
▸ C5AR1 P21730 1/20 0.53
▸ KISS1R Q969F8 3/20 0.52
▸ DPP3 Q9NY33 1/20 0.51
▸ OPRM1 P35372 2/20 0.50
▸ OPRK1 P41145 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29675079 0.96 CXCR4 (0.60) CXCR4NTSR2NTSR1SORT1KISS1R
SCHEMBL30273393 0.96 CXCR4 (0.61) CXCR4NTSR2NTSR1SORT1NPY1R
SCHEMBL28202049 0.96 CXCR4 (0.60) CXCR4NTSR2NTSR1SORT1KISS1R
Omiganan SCHEMBL27824120 0.95 CXCR4 (0.60) CXCR4NTSR2NTSR1SORT1NPY1R
SCHEMBL29674929 0.95 CXCR4 (0.59) CXCR4KISS1ROPRM1OPRK1
SCHEMBL29675119 0.95 CXCR4 (0.59) CXCR4KISS1ROPRM1OPRK1
Omiganan SCHEMBL29410943 0.94 CXCR4 (0.59) CXCR4NTSR2NTSR1SORT1NPY1R
SCHEMBL30343341 0.90 DPP3 (0.55) CXCR4NTSR2NTSR1SORT1NPY1R
SCHEMBL31506622 0.90 DPP3 (0.61) CXCR4NTSR2NTSR1SORT1F13A1
SCHEMBL30735734 0.90 CXCR4 (0.58) CXCR4NTSR2NTSR1SORT1F13A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409593-A1 COMPOSITION FOR SUPPRESSION OF INFLAMMATORY DISEASES COMPRISING BIOCOMPATIBLE POLYPEPTIDE TO WHICH FUNCTIONAL PEPTIDE IS CONJUGATED BIOVIT CO., LTD. (KR) 2024-12-12 — — US claimed
WO-2024005225-A1 FILTER COATED WITH FUNCTIONAL POLYPEPTIDE 주식회사 바이오빛 2024-01-04 — — WO claimed
WO-2023229053-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS DISEASES 주식회사 바이오빛 2023-11-30 — — WO claimed
US-11578106-B2 Surfactant adhesive composition TME Therapeutics Co., Ltd. (KR) 2023-02-14 — — US claimed
WO-2022145518-A1 HARD COATING COMPOSITION COMPRISING ANTIBACTERIAL PROTEIN AND METHOD FOR PREPARING SAME 주식회사 바이오빛 2022-07-07 — — WO claimed
US-20220175968-A1 NON-ACTIVE LIPID NANOPARTICLES WITH NON-VIRAL, CAPSID FREE DNA GENERATION BIO CO. 2022-06-09 — — US claimed
WO-2022114521-A1 COMPOSITION FOR SUPPRESSION OF INFLAMMATORY DISEASES COMPRISING BIOCOMPATIBLE POLYPEPTIDE TO WHICH FUNCTIONAL PEPTIDE IS CONJUGATED 주식회사 바이오빛 2022-06-02 — — WO claimed
WO-2022065805-A1 RECOMBINANT POLYPEPTIDE DERIVED FROM MUSSEL ADHESIVE PROTEIN AND USE THEREOF 주식회사 바이오빛 2022-03-31 — — WO claimed
EP-3574909-B1 POLYELECTROLYTE MULTILAYER COMPRISING SILVER FOR WOUND HEALING IMBED BIOSCIENCES INC (US) 2026-03-04 — — EP disclosed
WO-2026042045-A1 INDOLICIDINE-CONTAINING COMPOSITIONS FOR PERSONAL CARE/HYGIENE APPLICATIONS ITC LIMITED (IN) 2026-02-26 — — WO disclosed
US-20260000805-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING IMBED BIOSCIENCES INC (US) 2026-01-01 — — US disclosed
US-12453776-B2 Lipids and compositions for the delivery of therapeutics ARBUTUS BIOPHARMA CORPORATION (CA) 2025-10-28 — — US disclosed
US-RE50618-E1 Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same PHARMAIN CORPORATION (US) 2025-10-07 — — US disclosed
US-12409247-B2 Methods and compositions for wound healing IMBED BIOSCIENCES INC. (US) 2025-09-09 — — US disclosed
EP-3995158-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING Imbed Biosciences, Inc. (US) 2022-05-11 — — EP disclosed
US-11324815-B2 Vaccine constructs and uses thereof against Staphylococcus infections Socpra—Sciences et Genie, S.E.C. (CA) 2022-05-10 — — US disclosed
EP-3978605-A1 ANTIMICROBIAL AGENTS AGAINST SALMONELLA BACTERIA Lysando AG (LI) 2022-04-06 — — EP disclosed
WO-2022065805-A1 RECOMBINANT POLYPEPTIDE DERIVED FROM MUSSEL ADHESIVE PROTEIN AND USE THEREOF 주식회사 바이오빛 2022-03-31 — — WO disclosed
EP-3541406-B1 NEW ANTIMICROBIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS LYSANDO AG (LI) 2022-03-16 — — EP disclosed
US-20220064623-A1 ENDOLYSIN VARIANT SASINAPAS CO., LTD. (TH) 2022-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12453776-B2 Lipids and compositions for the delivery of therapeutics PHOSPHO1, MBOAT1, SGMS1 CXCR4 1051/4885NTSR2 2663/4885NTSR1 2151/4885
US-20260000805-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING PCNA, ARG1, PLOD3 CXCR4 3298/4885NTSR2 4027/4885NTSR1 3816/4885
US-20220175968-A1 NON-ACTIVE LIPID NANOPARTICLES WITH NON-VIRAL, CAPSID FREE DNA POLN, DNA2, NPC1 CXCR4 2002/4885NTSR2 4418/4885NTSR1 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback